Skip to Main Content

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. 

A nudge from AI pinpoints ketamine as a potential rare disease treatment 


In the seven difficult years since their son Mateo was diagnosed with a rare disease called ANDP syndrome, Victoria Malvagno and Frank Solorzano have been waiting for medicine to catch up with their lives. In 2019, the ANDP community got a breakthrough — not from a drug developer, or a doctor’s office, but from an artificial intelligence tool. The system, called mediKanren, sifted through millions of abstracts and rapidly pinpointed an unexpected target: ketamine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.